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BONE TURNOVER MARKERS (BTMS) IN THE SYNOVIAL FLUID IN THE
PATIENTS WITH OSTEOARTHRITIS CORRELATES WITH THE SERUM
LEVEL OF BTMS THOUGH SOME PATIENTS WITH OSTEOPOROSIS
EXHIBIT MISMATCHED INCREASE IN BONE RESORPTION ACTIVITY
IN SYNOVIAL FLUID
Y. Saita y,z, K. Kurata z, T. Sato z, S. Fukasaku z, K. Kaneko y, M. Nemoto z.
yDept. of Orthopaedics, Juntendo Univ., Tokyo, Japan; zDept. of Orthopedic
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Purpose: Little is known regarding the relationships between the
osteoarthritis (OA) and osteoporosis especially for the link between the
subchondral bone remodeling and pathology of OA. In the patients with
severe OA, articular cartilages wear down and subchondral bones
become exposed. We hypothesized that BTMs in the synovial ﬂuid
would be related to the pathology of OA, and evaluated them in the
patients with knee OA.
Methods: Twenty seven knees in twenty one postmenopausal women
with advanced-stage knee osteoarthritis (Kellgren-Lawrence >2) were
analyzed in this study. The average age of patients was 73.4 (range, 52–
83 years). Knee pain was evaluated using visual analogue scales (VAS)
and outcome measure for Japanese patients with knee osteoarthritis
(JKOM). Tartrate-resistant acidic phosphatase 5b (TRAcP5b) activity and
procollagen 1 N-terminal peptide (P1NP) concentrationwere measured
both in the serum and synovial ﬂuid. Bone mineral density (BMD) was
measured in digital image processing method at second metacarpal
bone. In statistics, Spearman’s rank correlation coefﬁcient (r) and stat-
istical signiﬁcance (p) were calculated using GraphPad Prismversion 6.0
(GraphPad Software). The Mann-Whitney U test was used to compare
differences between two independent groups. The values of p < 0.05
were considered to be statistically signiﬁcant.
Results: The serum level of TRAcP5b and P1NP were 444.7  198.9
(average  SD, mU/dL) and 49.8  20.33 mg/L respectively. In the
synovial ﬂuid, the activity of TRAcP5b was 250.4  108.1 mU/dL and the
concentration of P1NP was 402.1  247.8 mg/L. The activity of TRAcP5b
in the synovial ﬂuid was low compared with the serum TRAcP5b
(synovial ﬂuid/serum ratio was 0.56  0.35), on the other hand, the
concentration of P1NP in the synovial ﬂuid was high (synovial ﬂuid/
serum ratio was 8.3  4.2). The BTMs in the synovial ﬂuid signiﬁcantly
correlated with the serum level of BTMs (r¼ 0.44, p¼ 0.02 for TRAcP5b,
r ¼ 0.60, p ¼ 0.001 for P1NP) indicating that systematic bone remod-
eling statements are related to the bone remodeling state in the peri-
articular lesion. However, interestingly, in three knees in three patients,
the activity of TRAcP5b in synovial ﬂuid was higher than serum
TRAcP5b activity. Synovial ﬂuid/serum ratio was 1.43  0.09 in these
patients and this was signiﬁcantly higher than the other knees (n ¼ 24,
0.45  0.16, p ¼ 0.0007). In these three patients with increased bone
resorption activity in synovial ﬂuid, pain scores tended to high (not
signiﬁcant), though BMD was signiﬁcantly lower than the other
patients (1.77 versus 2.12 mmAl, p ¼ 0.03). This suggest that, in some
patient (3/27 knees in this study), subchondral bone fragility may be
involved in the pathology of knee OA and would cause of knee pain as
well. With regard to the measurement of BMD, the value of BMD was
2.07  0.28 mmAl on average, and almost half (10/21) of the patients
diagnosed as osteoporosis (deﬁned as the BMD below 70% from young
adult mean). In the patients with osteoporosis, the synovial ﬂuid/serum
TRAcP5b activity ratio (0.66 on average) was slightly higher than those
with the other patient (0.48 on average) but there was not signiﬁcant
difference. Pain scores did not correlate with the BTMs neither in the
serum nor synovial ﬂuid. Severity of knee OA was not correlated with
the BMD nor BTMs.
Conclusions: We revealed that BTMs in synovial ﬂuid of knee OA was
related to the systematic bone remodeling statement in the majority of
patients; however, in some patients with osteoporosis increased in
bone resorption activity in synovial ﬂuid, suggesting that suppression
for bone resorption activity using anti-resorptive agents could be one of
the effective treatments for knee OA in such individuals.
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EFFECT OF VITAMIN D SUPPLEMENTATION ON RADIOGRAPHIC KNEE
OSTEOARTHRITIS
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Purpose: At present there are no licenced treatments that can prevent
structural progression of osteoarthritis and current treatments are
aimed at minimising pain and maximising function. Epidemiological
data suggest that low dietary intake of vitamin D and low serum 25-
hydroxyvitamin D3 levels are associated with radiological progression
in knee osteoarthritis. The vitamin D Evaluation in knee Osteoarthritis
(VIDEO) study aimed to assess whether adding vitamin D to the diet
through a supplement can prevent the deterioration of osteoarthritis at
the knee joint, as determined by the change in radiographic joint space
width (JSW) in the medial compartment.
Methods: 474 patients with knee osteoarthritis from ﬁve hospitals were
recruited into a double-blind, randomised, placebo controlled trial of
800 IU cholecalciferol daily or placebo for 3 years. X-rays of both the
index and contralateral knee were taken at baseline, 12 months and 36
months. The minimum lateral and medial JSW were measured blind to
visit order and treatment allocation using Oxmorf software. To assess
the change in JSW over time, analysis was performed using a linear
mixed regression model with ﬁxed effects for treatment, time, treat-
ment by time and adjustment for; baseline JSW, centre, gender, glu-
cosamine use, age and BMI. The effect of treatment on the proportion of
patients with clinically signiﬁcant progression (JSN > 0.5 mm in the
index knee) at 3 years was obtained using a Poisson regression model
with robust error estimates to obtain relative risk (RR), with adjustment
for baseline index JSW, gender, glucosamine use, age, BMI and centre.
Each knee was graded according to the Kellgren and Lawrence (K&L,
1957, 1963) scale. Logistic regressionwas used to calculate an odds ratio
(OR) for increase of K&L grades between the vitamin D and control
groups. All statistical analyses were performed using Stata/IC version
12.1.
Results: The difference in joint space narrowing per year in the medial
compartment of the index knee between the treatment and control
groups was 0.07 mm/year (vitamin D 0.01 mm/year; placebo 0.08
mm/year; 95% CI 0.15–0.30, p ¼ 0.51). In the lateral compartment, the
equivalent difference between the two groups was 0.07 mm/year
(vitamin D0.11mm/year, placebo0.18mm/year; 95% CI0.15–0.30).
39% of patients in the treatment group and 37% of patients in the pla-
cebo group showed a clinically signiﬁcant progression of JSN (>0.5 mm)
at 3 years compared to baseline. The unadjusted relative risk of clin-
ically signiﬁcant progression of JSN for the vitamin D group relative to
the placebo group was 1.05 (95% CI 0.77–1.44, p ¼ 0.76). The adjusted
relative risk was 1.03 (95% CI 0.76–1.40, p ¼ 0.83). The odds ratio of a
higher K&L grade per year in the index knee was calculated as 1.07 for
the treatment group versus the placebo group (95% CI, 0.88–1.31).
Conclusion: There was no evidence of a signiﬁcant difference in joint
space narrowing in either the medial or lateral compartment of the
index knee between the vitamin D and placebo group. Further, there
was no difference in the proportion of patients with clinically sig-
niﬁcant progression of JSN between the two groups. The odds of a
higher K&L grade per year was unaffected by the treatment type. This
would suggest that vitamin D does not have a signiﬁcant effect on the
radiographic progression of knee osteoarthritis. However, the rate of
narrowing in the placebo group was signiﬁcantly lower than expected.
Analysis of serum vitamin D levels is now being undertaken which may
give further insight.
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ANTI-OSTEOPOROSIS ACTIVITY OF A NOVEL HERBAL FORMULA
BHH10 ON OVARIECTOMY-INDUCED BONE LOSS IN RATS
J-E. Huh, S-J. Kim, H. Yang, J-W. Kang, D-W. Nam, D-Y. Choi, D-S. Park,
J-D. Lee. Kyung Hee Univ., Seoul, Republic of Korea
Aim of the study: BHH10, an herbal formulation, contains Astragalus
membranaceus, Cinnamomum cassia, and Phellodendron amurensis,
and has been used for osteoporosis and inﬂammatory-related diseases.
This study systematically investigated the effect of the traditional
medicine BHH10 on bone metabolism in ovariectomized (OVX) rats.
Material and methods: Six-month-old female Sprague-Dawley rats
were randomly divided into a sham-operated group (SHAM) and six
OVX subgroups: OVX with vehicle (OVX); OVX with alendronate (ALN,
